Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors are rapidly transforming the care of patients with esophagogastric cancer. Particularly, anti-PD-1 therapy has demonstrated promising efficacy in metastatic and resectable disease. In this review, the authors discuss landmark clinical trials, highlight challenges and opportunities in this field, and propose potential directions for future work.
No takes yet. Share an insight, caveat, or question.
Jazieh et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: